YD Bio Statistics
Total Valuation
YD Bio has a market cap or net worth of $416.49 million. The enterprise value is $413.83 million.
| Market Cap | 416.49M |
| Enterprise Value | 413.83M |
Important Dates
The last earnings date was Monday, August 31, 2026, after market close.
| Earnings Date | Aug 31, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
YD Bio has 70.83 million shares outstanding. The number of shares has decreased by -13.49% in one year.
| Current Share Class | 70.83M |
| Shares Outstanding | 70.83M |
| Shares Change (YoY) | -13.49% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 76.78% |
| Owned by Institutions (%) | 0.46% |
| Float | 16.19M |
Valuation Ratios
The trailing PE ratio is 1,362.13.
| PE Ratio | 1,362.13 |
| Forward PE | n/a |
| PS Ratio | 336.06 |
| Forward PS | n/a |
| PB Ratio | 93.11 |
| P/TBV Ratio | 208.22 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | 1,353.44 |
| EV / Sales | 333.92 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 5.23, with a Debt / Equity ratio of 0.00.
| Current Ratio | 5.23 |
| Quick Ratio | 2.70 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | n/a |
| Return on Invested Capital (ROIC) | -360.63% |
| Return on Capital Employed (ROCE) | -72.88% |
| Weighted Average Cost of Capital (WACC) | 3.39% |
| Revenue Per Employee | $82,621 |
| Profits Per Employee | $20,384 |
| Employee Count | 15 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -24 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -67.69% in the last 52 weeks. The beta is -0.16, so YD Bio's price volatility has been lower than the market average.
| Beta (5Y) | -0.16 |
| 52-Week Price Change | -67.69% |
| 50-Day Moving Average | 4.08 |
| 200-Day Moving Average | 6.05 |
| Relative Strength Index (RSI) | 55.06 |
| Average Volume (20 Days) | 619,714 |
Short Selling Information
The latest short interest is 42,960, so 0.06% of the outstanding shares have been sold short.
| Short Interest | 42,960 |
| Short Previous Month | 13,293 |
| Short % of Shares Out | 0.06% |
| Short % of Float | 0.27% |
| Short Ratio (days to cover) | 0.12 |
Income Statement
In the last 12 months, YD Bio had revenue of $1.24 million and earned $305,762 in profits. Earnings per share was $0.00.
| Revenue | 1.24M |
| Gross Profit | 366,845 |
| Operating Income | -6.55M |
| Pretax Income | 305,738 |
| Net Income | 305,762 |
| EBITDA | -6.34M |
| EBIT | -6.55M |
| Earnings Per Share (EPS) | $0.00 |
Balance Sheet
The company has $2.66 million in cash and $5,002 in debt, with a net cash position of $2.66 million or $0.04 per share.
| Cash & Cash Equivalents | 2.66M |
| Total Debt | 5,002 |
| Net Cash | 2.66M |
| Net Cash Per Share | $0.04 |
| Equity (Book Value) | 4.47M |
| Book Value Per Share | 0.06 |
| Working Capital | 4.52M |
Cash Flow
In the last 12 months, operating cash flow was -$7.26 million and capital expenditures -$1.45 million, giving a free cash flow of -$8.70 million.
| Operating Cash Flow | -7.26M |
| Capital Expenditures | -1.45M |
| Depreciation & Amortization | 210,600 |
| Net Borrowing | n/a |
| Free Cash Flow | -8.70M |
| FCF Per Share | -$0.12 |
Margins
Gross margin is 29.60%, with operating and profit margins of -528.72% and 24.67%.
| Gross Margin | 29.60% |
| Operating Margin | -528.72% |
| Pretax Margin | 24.67% |
| Profit Margin | 24.67% |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
YD Bio does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | 13.49% |
| Shareholder Yield | 13.49% |
| Earnings Yield | 0.07% |
| FCF Yield | -2.09% |
Analyst Forecast
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
YD Bio has an Altman Z-Score of 67.4 and a Piotroski F-Score of 1.
| Altman Z-Score | 67.4 |
| Piotroski F-Score | 1 |